Advertisement
J. Lipid Res.
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH
QUICK SEARCH:   [advanced]


     

A more recent version of this article appeared on December 1, 2005

Papers In Press, published online ahead of print September 26, 2005
J. Lipid Res., doi:10.1194/jlr.M500390-JLR200
This Article
Right arrow Full Text (Accepted Manuscript)
Right arrow All Versions of this Article:
M500390-JLR200v1
46/12/2595    most recent
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrowRequest Permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Hanniman, E. A.
Right arrow Articles by Sinal, C. J.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Hanniman, E. A.
Right arrow Articles by Sinal, C. J.
Social Bookmarking
Add to CiteULike   Add to Complore   Add to Connotea   Add to Del.icio.us   Add to Digg   Add to Reddit   Add to Technorati  
What's this?

Submitted on August 29, 2005
Revised on September 15, 2005
Accepted on September 26, 2005

Loss of functional farnesoid X-receptor increases atherosclerotic lesions in apolipoprotein E-deficient mice

Elyisha A. Hanniman, Gilles Lambert, Tanya C. McCarthy, and Christopher J. Sinal

Pharmacology Dept., Dalhousie University, Halifax, Nova Scotia B3H 1X5

Corresponding Author: csinal{at}dal.ca

The farnesoid X receptor (FXR) is a bile acid-activated transcription factor that regulates the expression of genes critical for bile acid and lipid homeostasis. The present study was undertaken to investigate the pathological consequences of loss of FXR function on the risk and severity of atherosclerosis. For this purpose, FXR–/– mice were crossed with apolipoprotein E-deficient (ApoE–/–) mice to generate FXR–/–ApoE–/– mice. Challenging these mice with a high fat, high cholesterol (HF/HC) diet resulted in reduced weight gain and decreased survival compared to wildtype, FXR–/– and ApoE–/– mice. FXR–/–ApoE–/– mice also had the highest total plasma lipids and the most atherogenic lipoprotein profile. Livers from FXR–/– and FXR–/–ApoE–/– mice exhibited marked lipid accumulation, focal necrosis accompanied by increased levels of plasma aspartate amino transferase and increased inflammatory gene expression. Measurement of en face lesion area of HF/HC challenged mice revealed that while FXR–/– mice did not develop atherosclerosis, FXR–/–ApoE–/– mice had approximately double the lesion area compared to ApoE–/– mice. In conclusion, loss of FXR function is associated with decreased survival, increased severity of defects in lipid metabolism and more extensive aortic plaque formation in a mouse model of atherosclerotic disease.


Add to CiteULike CiteULike   Add to Complore Complore   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us   Add to Digg Digg   Add to Reddit Reddit   Add to Technorati Technorati    What's this?


This article has been cited by other articles:


Home page
 Am. J. Physiol. Renal Physiol.Home page
X. X. Wang, T. Jiang, Y. Shen, L. Adorini, M. Pruzanski, F. J. Gonzalez, P. Scherzer, L. Lewis, S. Miyazaki-Anzai, and M. Levi
The farnesoid X receptor modulates renal lipid metabolism and diet-induced renal inflammation, fibrosis, and proteinuria
Am J Physiol Renal Physiol, December 1, 2009; 297(6): F1587 - F1596.
[Abstract] [Full Text] [PDF]

Home page
 J. Lipid Res.Home page
H. B. Hartman, S. J. Gardell, C. J. Petucci, S. Wang, J. A. Krueger, and M. J. Evans
Activation of farnesoid X receptor prevents atherosclerotic lesion formation in LDLR-/- and apoE-/- mice
J. Lipid Res., June 1, 2009; 50(6): 1090 - 1100.
[Abstract] [Full Text] [PDF]

Home page
 J. Lipid Res.Home page
H. B. Hartman, K. Lai, and M. J. Evans
Loss of small heterodimer partner expression in the liver protects against dyslipidemia
J. Lipid Res., February 1, 2009; 50(2): 193 - 203.
[Abstract] [Full Text] [PDF]

Home page
 Am. J. Physiol. Heart Circ. Physiol.Home page
A. Mencarelli, B. Renga, E. Distrutti, and S. Fiorucci
Antiatherosclerotic effect of farnesoid X receptor
Am J Physiol Heart Circ Physiol, February 1, 2009; 296(2): H272 - H281.
[Abstract] [Full Text] [PDF]

Home page
 J. Pharmacol. Exp. Ther.Home page
B. Kong, J. P. Luyendyk, O. Tawfik, and G. L. Guo
Farnesoid X Receptor Deficiency Induces Nonalcoholic Steatohepatitis in Low-Density Lipoprotein Receptor-Knockout Mice Fed a High-Fat Diet
J. Pharmacol. Exp. Ther., January 1, 2009; 328(1): 116 - 122.
[Abstract] [Full Text] [PDF]

Home page
 Cardiovasc ResHome page
Q. Zhang, F. He, R. Kuruba, X. Gao, A. Wilson, J. Li, T. R. Billiar, B. R. Pitt, W. Xie, and S. Li
FXR-mediated regulation of angiotensin type 2 receptor expression in vascular smooth muscle cells
Cardiovasc Res, February 1, 2008; 77(3): 560 - 569.
[Abstract] [Full Text] [PDF]

Home page
 Arterioscler. Thromb. Vasc. Bio.Home page
Y. T.Y. Li, K. E. Swales, G. J. Thomas, T. D. Warner, and D. Bishop-Bailey
Farnesoid X Receptor Ligands Inhibit Vascular Smooth Muscle Cell Inflammation and Migration
Arterioscler Thromb Vasc Biol, December 1, 2007; 27(12): 2606 - 2611.
[Abstract] [Full Text] [PDF]

Home page
 J. Lipid Res.Home page
E. A. Hanniman, G. Lambert, Y. Inoue, F. J. Gonzalez, and C. J. Sinal
Apolipoprotein A-IV is regulated by nutritional and metabolic stress: involvement of glucocorticoids, HNF-4{alpha}, and PGC-1{alpha}
J. Lipid Res., November 1, 2006; 47(11): 2503 - 2514.
[Abstract] [Full Text] [PDF]

Home page
 Arterioscler. Thromb. Vasc. Bio.Home page
Y. Zhang, X. Wang, C. Vales, F. Y. Lee, H. Lee, A. J. Lusis, and P. A. Edwards
FXR Deficiency Causes Reduced Atherosclerosis in Ldlr-/- Mice
Arterioscler Thromb Vasc Biol, October 1, 2006; 26(10): 2316 - 2321.
[Abstract] [Full Text] [PDF]

Home page
 EndocrinologyHome page
S. Caron, B. Cariou, and B. Staels
FXR: More than a Bile Acid Receptor?
Endocrinology, September 1, 2006; 147(9): 4022 - 4024.
[Full Text] [PDF]

Home page
 EndocrinologyHome page
S. Wang, K. Lai, F. J. Moy, A. Bhat, H. B. Hartman, and M. J. Evans
The Nuclear Hormone Receptor Farnesoid X Receptor (FXR) Is Activated by Androsterone
Endocrinology, September 1, 2006; 147(9): 4025 - 4033.
[Abstract] [Full Text] [PDF]


HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH
 All ASBMB Journals   Journal of Biological Chemistry 
 Molecular and Cellular Proteomics   ASBMB Today 
Copyright © 2005 by the American Society for Biochemistry and Molecular Biology.
Advertisement
spacer
Advertisement
Advertisement